We next normalized IFN-JAK signaling by treating differentiating DS/CHD iPSCs with 1 μM of tofacitinib, a JAK1/3 inhibitor (hereafter referred to as JAKi). This evidence concerns the gene JAK1 and coronary artery disorder.